Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cumberland Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Cumberland Pharmaceuticals Inc.’s stock price such as:

• Cumberland Pharmaceuticals Inc.’s current stock price and volume
• Why Cumberland Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for CPIX from analysts
• CPIX’s stock price momentum as measured by its relative strength

About Cumberland Pharmaceuticals Inc. (CPIX)

Before we jump into Cumberland Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Want to learn more about Cumberland Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cumberland Pharmaceuticals Inc..

Cumberland Pharmaceuticals Inc.’s Stock Price as of Market Close

As of December 02, 2025, 9:58 AM, CST, Cumberland Pharmaceuticals Inc.’s stock price was $2.210.

Cumberland Pharmaceuticals Inc. is up 1.84% from its previous closing price of $2.170.

During the last market session, Cumberland Pharmaceuticals Inc.’s stock traded between $2.200 and $2.210. Currently, there are approximately 14.96 million shares outstanding for Cumberland Pharmaceuticals Inc..

Cumberland Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cumberland Pharmaceuticals Inc. Stock Price History

Cumberland Pharmaceuticals Inc.’s (CPIX) price is currently down 2.21% so far this month.

During the month of December, Cumberland Pharmaceuticals Inc.’s stock price has reached a high of $2.470 and a low of $2.112.

Over the last year, Cumberland Pharmaceuticals Inc. has hit prices as high as $7.250 and as low as $1.090. Year to date, Cumberland Pharmaceuticals Inc.’s stock is down 6.75%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cumberland Pharmaceuticals Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were analysts who downgraded Cumberland Pharmaceuticals Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cumberland Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cumberland Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cumberland Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cumberland Pharmaceuticals Inc. (CPIX) by visiting AAII Stock Evaluator.

Relative Price Strength of Cumberland Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Cumberland Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 52.09%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Cumberland Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cumberland Pharmaceuticals Inc. Stock Price: Bottom Line

As of December 2, 2025, Cumberland Pharmaceuticals Inc.’s stock price is $2.210, which is up 1.84% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cumberland Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.